Gene Therapy for Blood Disorders

Memo

Revolutionary gene therapies are redefining the treatment of blood diseases. With an approved gene therapy treatment for β-thalassemia in the EU, and hemophilia candidates seeking 2020 approval in the USA and beyond, pioneers in the space must overcome hurdles they have never previously encountered to transform their clinical candidates into a commercial reality. Gene Therapy for Blood Disorders will unite industry leaders across the blood disease space to delve into the specific clinical and commercial challenges faced by companies developing gene therapies for hemophilia, sickle cell disease and β-thalassemia. Evaluate the best strategies for a commercial launch in blood disease, optimize your trial design, gain insights on revolutionary novel technologies, and ultimately enhance your current hematology gene therapy program to bring transformative treatments to patients more quickly and efficiently. URLs: Tickets https://go.evvnt.com/552809-1?pid=5569Brochure https://go.evvnt.com/552809-3?pid=5569 Prices:Conference Only Industry - Early Rate: USD 2299.00,Conference Only Industry - Standard Rate: USD 2899.00,Conference Only Academic - Early Rate: USD 1899.00,Conference Only Academic - Standard Rate: USD 2499.00. Speakers: Grant Blouse Catalyst Biosciences, Julianne Bruno CRISPR Therapeutics, John Chapin CRISPR Therapeutics, Colleen Dansereau Boston Children’s Hospital, Mrudula Donepudi Editas Medicine, Catalina Driscoll Sanofi Genzyme, Dean Falb LogicBio, Meghan Gallagher bluebird bio, Nicolas Garnier Pfizer Rare Disease, Angela Johnson Sigilon Therapeutics, Paul Monahan Spark Therapeutics, Dawn Rotellini National Hemophilia Foundation, Eileen Sawyer uniQure, Julian Down Poseida Therapeutics, Matt Trudeau bluebird bio, Sander van Deventer uniQure, John Woolley University of Liverpool. Time: 9:00 am to 5:00 pm. Venue details: Courtyard by Marriott Boston Downtown, 275 Tremont Street, Boston, Massachusetts, 02116, United States.